Heart Disease Health Center

Font Size
A
A
A

FDA Enters Stent Safety Debate

Proposed Guidelines for New Drug-Coated Stents Stress Patient Issues
By Daniel J. DeNoon
WebMD Health News
Reviewed by Louise Chang, MD

March 26, 2008 -- To get new drug-coated stents approved, makers of the artery-opening devices will have to focus on patient issues, FDA draft guidelines say.

After balloon angioplasty unclogs arteries, mesh tubes called stents are used to prop the arteries open. Newer stents are coated with chemicals that prevent reclogging. But these drug-eluting stents slow healing, adding a small but serious risk of deadly blood clots.

After the FDA approved three of these devices, doctors have struggled to understand exactly when drug-coated stents should be used, and how best to prevent blood clots. Currently, it's recommended that patients getting these stents should receive anticlotting treatment with Plavix for at least a year.

Proposed Guidelines for Drug-Eluting Stents

Now the FDA has proposed new guidelines for makers of new drug-eluting stents. To get approved, the agency suggests, stent makers will have to perform studies showing:

  • The effects the new devices have on reducing patient deaths, heart attacks, and need for repeat procedures.
  • Overall rates of death and heart attack in patients receiving the new stents.
  • The rate at which blood clots occur in patients receiving the new stents.
  • The impact of anticlotting treatment on patients, including how well patients comply with the treatment, how often patients need extended anticlotting treatment, how often anticlotting treatment has to be interrupted, the number of surgical procedures deferred due to anticlotting treatment, and the rate of significant bleeding complications of anticlotting treatment.

In addition, the FDA requires information on the safety of all drugs given off by the stents.

"This draft guidance is part of FDA's ongoing effort to provide regulated industry with recommendations on measures that can minimize the risks while preserving for patients the benefits of drug-eluting stents," Daniel G. Schultz, MD, director of the FDA's Center for Devices and Radiological Health, says in a news release.

The proposed guidelines also help device makers understand what the FDA needs for approval of products that are both medical devices and drugs.

These aren't small issues. Every year, about a million Americans undergo procedures to treat blocked arteries near the heart. About 650,000 of these patients receive drug-eluting stents.

The FDA plans to hold public hearings to discuss the proposed guidelines.

heart health newsletter

Health information tailored for those living with heart disease. Sign up today to receive WebMD's trusted Heart newsletter.

webMD Video

Show or hide information about video: Exercise vs. Diet   Exercise vs. Diet

Being overweight is a heart disease risk factor, but there may be something more women of all shapes and sizes should worry about.

Watch Video: Exercise vs. Diet (opens in a new window)

Show or hide information about video: Detecting Women's Heart Disease   Detecting Women's Heart Disease

Show or hide information about video: At Risk for Heart Disease?   At Risk for Heart Disease?

Show or hide information about video: Predicting Heart Disease   Predicting Heart Disease

Show or hide information about video: Fish Oil Heart Study   Fish Oil Heart Study

Advertise on Fox News Channel, FOXNews.com and FOX News Radio Jobs at FOX News Channel. Internships at FOX News Channel (now accepting Fall interns).
Terms of use. Privacy Statement. For FOXNews.com comments write to foxnewsonline@foxnews.com; For FOX News Channel comments write to comments@foxnews.com
© Associated Press. All rights reserved.
SMARTMONEY ® © 2006 SmartMoney. SmartMoney is a joint publishing venture of Dow Jones & Company, Inc. and Hearst SM Partnership. All Rights Reserved.
All quotes delayed by 20 minutes. Delayed quotes provided by ComStock.
Historical prices and fundamental data provided by Hemscott, Inc.
Mutual fund data provided by Lipper. Mutual Fund NAVs are as of previous day's close.
Earnings estimates provided by Zacks Investment Research.
Upgrades and downgrades provided by Briefing.com.
This material may not be published, broadcast, rewritten, or redistributed. © 2006 FOX News Network, LLC. All rights reserved. All market data delayed 20 minutes.